Tag: EUA; VRBPAC; Janssen Biotech Inc.; Professor Luke O’Neill; Newstalk; SARS-CoV-2 variant B.1.351;Janssen-Cilag International;European Medicines Agency; VRBPAC;

Johnson & Johnson’s adenovirus vector based vaccine – a game changer?

Post author By miriammyvaccinecom
Post date February 17, 2021
2 Comments on Johnson & Johnson’s adenovirus vector based vaccine – a game changer?

Johnson & Johnson’s adenovirus vector-based vaccine, developed by its subsidiary Janssen Biotech Inc. reported 66% overall vaccine efficacy with a single dose after 28 days in a global Phase III trial with 43,783 participants. However, efficacies were different at different trial locations: 72% efficacy in the US, 66% in Latin America, and 57% in South […]

Tags EUA; VRBPAC; Janssen Biotech Inc.; Professor Luke O'Neill; Newstalk; SARS-CoV-2 variant B.1.351;Janssen-Cilag International;European Medicines Agency; VRBPAC;